Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia

Assessment of measurable residual disease (MRD) provides prognostic information in acute myeloid leukemia (AML). However, the utility of MRD with venetoclax-based lower intensity regimens is unknown. We analyzed the prognostic value of achieving a negative MRD in older/“unfit” patients with AML rece...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Blood Adv
Hoofdauteurs: Maiti, Abhishek, DiNardo, Courtney D., Wang, Sa A., Jorgensen, Jeffrey, Kadia, Tapan M., Daver, Naval G., Short, Nicholas J., Yilmaz, Musa, Pemmaraju, Naveen, Borthakur, Gautam, Bose, Prithviraj, Issa, Ghayas C., Ferrajoli, Alessandra, Jabbour, Elias J., Jain, Nitin, Garcia-Manero, Guillermo, Ohanian, Maro, Takahashi, Koichi, Montalban-Bravo, Guillermo, Masarova, Lucia, Burger, Jan A., Thompson, Philip A., Verstovsek, Srdan, Sasaki, Koji, Andreeff, Michael, Rausch, Caitlin R., Montalbano, Kathryn S., Pierce, Sherry, Qiao, Wei, Ning, Jing, Kantarjian, Hagop M., Konopleva, Marina Y., Ravandi, Farhad
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Society of Hematology 2021
Onderwerpen:
Clinical Trials and Observations
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8045494/
https://ncbi.nlm.nih.gov/pubmed/33792630
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020003717
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items